SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-205557
Filing Date
2023-08-08
Accepted
2023-08-08 07:05:28
Documents
14
Period of Report
2023-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d541674d8k.htm   iXBRL 8-K 25114
2 EX-99.1 d541674dex991.htm EX-99.1 103990
6 GRAPHIC g541674g0808015732284.jpg GRAPHIC 5859
  Complete submission text file 0001193125-23-205557.txt   272148

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20230808.xsd EX-101.SCH 2867
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20230808_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20230808_pre.xml EX-101.PRE 10823
8 EXTRACTED XBRL INSTANCE DOCUMENT d541674d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 231149258
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences